JP2018537128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537128A5 JP2018537128A5 JP2018548246A JP2018548246A JP2018537128A5 JP 2018537128 A5 JP2018537128 A5 JP 2018537128A5 JP 2018548246 A JP2018548246 A JP 2018548246A JP 2018548246 A JP2018548246 A JP 2018548246A JP 2018537128 A5 JP2018537128 A5 JP 2018537128A5
- Authority
- JP
- Japan
- Prior art keywords
- individual
- nras
- kras
- cell
- multiple myeloma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021165655A JP2022000059A (ja) | 2015-12-03 | 2021-10-07 | 骨髄腫の治療または進行のモニタリング |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015905013A AU2015905013A0 (en) | 2015-12-03 | Monitoring treatment or progression of myeloma | |
| AU2015905013 | 2015-12-03 | ||
| AU2016903019A AU2016903019A0 (en) | 2016-08-01 | Monitoring treatment or progression of myeloma (2) | |
| AU2016903019 | 2016-08-01 | ||
| PCT/AU2016/051191 WO2017091865A1 (en) | 2015-12-03 | 2016-12-02 | Monitoring treatment or progression of myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021165655A Division JP2022000059A (ja) | 2015-12-03 | 2021-10-07 | 骨髄腫の治療または進行のモニタリング |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018537128A JP2018537128A (ja) | 2018-12-20 |
| JP2018537128A5 true JP2018537128A5 (https=) | 2019-12-26 |
Family
ID=58796005
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548246A Pending JP2018537128A (ja) | 2015-12-03 | 2016-12-02 | 骨髄腫の治療または進行のモニタリング |
| JP2021165655A Pending JP2022000059A (ja) | 2015-12-03 | 2021-10-07 | 骨髄腫の治療または進行のモニタリング |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021165655A Pending JP2022000059A (ja) | 2015-12-03 | 2021-10-07 | 骨髄腫の治療または進行のモニタリング |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180282820A1 (https=) |
| EP (1) | EP3384050A4 (https=) |
| JP (2) | JP2018537128A (https=) |
| KR (1) | KR20180088690A (https=) |
| CN (1) | CN108603232A (https=) |
| AU (1) | AU2016363113A1 (https=) |
| CA (1) | CA3007426A1 (https=) |
| WO (1) | WO2017091865A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| AU2011358564B9 (en) | 2011-02-09 | 2017-07-13 | Natera, Inc | Methods for non-invasive prenatal ploidy calling |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| US20180173845A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| WO2016183106A1 (en) | 2015-05-11 | 2016-11-17 | Natera, Inc. | Methods and compositions for determining ploidy |
| WO2017181202A2 (en) | 2016-04-15 | 2017-10-19 | Natera, Inc. | Methods for lung cancer detection |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| AU2018288832B2 (en) | 2017-06-20 | 2025-03-06 | The Medical College Of Wisconsin, Inc. | Assessing transplant complication risk with total cell-free DNA |
| WO2019075251A2 (en) * | 2017-10-12 | 2019-04-18 | Nantomics, Llc | CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS |
| CN107881233A (zh) * | 2017-10-31 | 2018-04-06 | 天津协和华美医学诊断技术有限公司 | 一种检测骨髓瘤相关基因群的检测试剂盒 |
| JP2021506342A (ja) | 2017-12-14 | 2021-02-22 | ティーエーアイ ダイアグノスティックス インコーポレイテッドＴａｉ Ｄｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ． | 移植のための移植片適合性の評価 |
| CA3090426A1 (en) | 2018-04-14 | 2019-10-17 | Natera, Inc. | Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna |
| WO2019207439A1 (en) * | 2018-04-23 | 2019-10-31 | Inivata Ltd. | Method for predicting and monitoring response to an immune checkpoint inhibitor |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| JP7407193B2 (ja) | 2018-08-08 | 2023-12-28 | イニヴァータ リミテッド | 可変の複製多重ｐｃｒを使用した配列決定方法 |
| EP3874042A4 (en) * | 2018-10-29 | 2023-06-28 | Molecular Stethoscope, Inc. | Characterization of bone marrow using cell-free messenger-rna |
| CA3117675A1 (en) * | 2018-10-30 | 2020-05-07 | Molecular Stethoscope, Inc. | Cell-free rna library preparations |
| EP3899033A4 (en) * | 2018-12-17 | 2022-10-19 | The Medical College of Wisconsin, Inc. | Assessing risk with total cell-free dna |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
| US20210087638A1 (en) * | 2019-09-23 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Next-generation sequencing assay for genomic characterization and minimal residual disease detection in the bone marrow, peripheral blood, and urine of multiple myeloma and smoldering myeloma patients |
| CN112760290A (zh) * | 2019-10-21 | 2021-05-07 | 郑州大学 | 携带突变的肿瘤驱动基因的干细胞及其用途 |
| WO2021092476A1 (en) * | 2019-11-06 | 2021-05-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and systems for analyzing nucleic acid molecules |
| FR3105738B1 (fr) * | 2019-12-26 | 2024-01-05 | P M B | Dispositif d’irradiation collaboratif |
| CN112698037B (zh) * | 2021-03-25 | 2021-06-25 | 北京积水潭医院 | 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用 |
| CN116679065B (zh) * | 2023-07-31 | 2023-11-14 | 北京大学人民医院 | 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110152357A1 (en) * | 2008-08-12 | 2011-06-23 | The Ohio State University | Micro-RNA-Based Compositions and Methods for the Diagnosis, Prognosis and Treatment of Multiple Myeloma |
| CA2779843A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| CA2855368A1 (en) * | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| CN113337604A (zh) * | 2013-03-15 | 2021-09-03 | 莱兰斯坦福初级大学评议会 | 循环核酸肿瘤标志物的鉴别和用途 |
| AU2014336987A1 (en) * | 2013-10-19 | 2016-04-14 | Trovagene, Inc. | Detecting mutations in disease over time |
-
2016
- 2016-12-02 EP EP16869417.2A patent/EP3384050A4/en not_active Withdrawn
- 2016-12-02 AU AU2016363113A patent/AU2016363113A1/en not_active Abandoned
- 2016-12-02 CA CA3007426A patent/CA3007426A1/en active Pending
- 2016-12-02 WO PCT/AU2016/051191 patent/WO2017091865A1/en not_active Ceased
- 2016-12-02 KR KR1020187018220A patent/KR20180088690A/ko not_active Withdrawn
- 2016-12-02 US US15/776,770 patent/US20180282820A1/en not_active Abandoned
- 2016-12-02 JP JP2018548246A patent/JP2018537128A/ja active Pending
- 2016-12-02 CN CN201680070973.XA patent/CN108603232A/zh active Pending
-
2021
- 2021-10-07 JP JP2021165655A patent/JP2022000059A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537128A5 (https=) | ||
| JP2022000059A5 (https=) | ||
| Digumarthy et al. | Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status? | |
| Jenkins et al. | Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non–small cell lung cancer | |
| Onidani et al. | Monitoring of cancer patients via next‐generation sequencing of patient‐derived circulating tumor cells and tumor DNA | |
| Weiss et al. | Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic | |
| Remon et al. | Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA | |
| De Mattos-Arruda et al. | Cell-free circulating tumour DNA as a liquid biopsy in breast cancer | |
| Ilié et al. | Pros: Can tissue biopsy be replaced by liquid biopsy? | |
| Zhao et al. | Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma | |
| Haselmann et al. | Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapy | |
| Douillard et al. | Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status | |
| Davis et al. | Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor–positive (HR+)/HER2-negative metastatic breast cancer | |
| JP6480349B2 (ja) | 血液でのｅｇｆｒ変異の検査 | |
| Payne et al. | Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma | |
| CN112805563A (zh) | 用于评估和/或治疗癌症的无细胞dna | |
| JP2022516152A (ja) | 転移性組織サンプルのトランスクリプトームデコンボリューション | |
| JP6100867B1 (ja) | 免疫状態の分析のための検査方法 | |
| van't Erve et al. | Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells | |
| JP2010539490A5 (https=) | ||
| Liang et al. | EGFR T790M ctDNA testing platforms and their role as companion diagnostics: correlation with clinical outcomes to EGFR-TKIs | |
| WO2018054254A1 (zh) | 一种鉴定样本中肿瘤负荷的方法和系统 | |
| Wang et al. | Impact of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage IA adenocarcinoma of the lung: Correlation between computed tomography images and EGFR and KRAS gene mutations | |
| JP2015210268A5 (https=) | ||
| Papastefanou et al. | Metabolic activity of primary uveal melanoma on PET/CT scan and its relationship with monosomy 3 and other prognostic factors |